RTTNews | Sep 20, 2021 09:18AM EDT

09:18 Monday, September 20, 2021 (RTTNews.com) - The Benitec Biopharma Inc. (BNTC), a pharmaceutical company engaged in the development of gene-silencing therapies, on Monday posted an increased loss for the fiscal year 2021, amidst a decline in revenue and rise in operating expenses.

The Melbourne-headquartered company reported a loss of $13.88 million or $3.23 per share for the year ended on June 30, compared to a loss of $8.27 million or $8.10 per share, reported for the last fiscal year.

The Australian company's loss from operations for the year rose to $13.59 million from $8.28 million reported for the year ended on June 30, 2020.

The company's total operating expenses for the twelve-month period were reported at $13.65 million, higher than $8.38 million posted a year ago.

The company generated its total revenue from customers at $0.059 million, less than $0.102 million reported for the 365-day long period that ended in June last year.

Read the original article on RTTNews ( https://www.rttnews.com/3226880/benitec-biopharma-posts-wider-loss-for-fy21.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved